Gili Hart
Director/Board Member chez ENLIVEX THERAPEUTICS LTD.
Fortune : 6 398 $ au 31/03/2024
Profil
Gili Hart is currently the Chief Executive Officer & Director at SpliSense Ltd., the Independent Director at Quicklizard Ltd., and the Independent Director at Enlivex Therapeutics Ltd.
Dr. Hart previously served as the Chief Executive Officer at OPKO Biologics Ltd.
from 2004 to 2017, the Chief Executive Officer at Mitoconix Bio Ltd.
from 2017 to 2020, and the VP-Pre-Clinical & Clinical Pharmacology at Prolor Biotech Ltd.
from 2009 to 2013.
Dr. Hart also held positions as the Vice President-Biologics at OPKO Health, Inc. and as a Director at Enlivex Therapeutics Ltd.
Dr. Hart has a graduate and doctorate degree from the Weizmann Institute of Science and an undergraduate degree from Technion Institute.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2023 | 1 688 ( 0,01% ) | 6 398 $ | 31/03/2024 |
Postes actifs de Gili Hart
| Sociétés | Poste | Début |
|---|---|---|
| ENLIVEX THERAPEUTICS LTD. | Director/Board Member | 01/01/2014 |
| QUICKLIZARD LTD | Director/Board Member | 21/02/2021 |
SpliSense Ltd.
 SpliSense Ltd. Pharmaceuticals: MajorHealth Technology SpliSense Ltd. engages in the development of targeted therapies for genetic diseases based on splicing modulation treating the underlying root cause of the disease. The company was founded on November 10, 2016 and is headquartered in Jerusalem, Israel. | Chief Executive Officer | 01/02/2020 |
Anciens postes connus de Gili Hart
| Sociétés | Poste | Fin |
|---|---|---|
| COLLPLANT BIOTECHNOLOGIES LTD. | Director/Board Member | 05/07/2023 |
Mitoconix Bio Ltd.
 Mitoconix Bio Ltd. BiotechnologyHealth Technology Mitoconix Bio Ltd. develops novel therapeutics to improve mitochondrial health as a disease-modifying therapeutics for neurodegenerative diseases. The company was founded by Daria Mochly-Rosen in August 2016 and is headquartered in Ness Ziona, Israel. | Chief Executive Officer | 01/01/2020 |
OPKO Biologics Ltd.
 OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Chief Executive Officer | 01/01/2017 |
Prolor Biotech Ltd.
 Prolor Biotech Ltd. BiotechnologyHealth Technology Prolor Biotech Ltd. develops proprietary versions of already-approved therapeutic proteins. The private company is based in Nes Ziona, Israel. | Corporate Officer/Principal | 01/01/2013 |
Enlivex Therapeutics Ltd. /Old/
 Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Director/Board Member | - |
Formation de Gili Hart
| Weizmann Institute of Science | Doctorate Degree |
| Technion Institute | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| OPKO HEALTH, INC. | Health Services |
| COLLPLANT BIOTECHNOLOGIES LTD. | Health Technology |
| QUICKLIZARD LTD | Technology Services |
| ENLIVEX THERAPEUTICS LTD. | Health Technology |
| Entreprise privées | 5 |
|---|---|
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | Health Technology |
Enlivex Therapeutics Ltd. /Old/
Enlivex Therapeutics Ltd. /Old/ Medical SpecialtiesHealth Technology Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded by Dror Mevorach in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
Prolor Biotech Ltd.
Prolor Biotech Ltd. BiotechnologyHealth Technology Prolor Biotech Ltd. develops proprietary versions of already-approved therapeutic proteins. The private company is based in Nes Ziona, Israel. | Health Technology |
Mitoconix Bio Ltd.
Mitoconix Bio Ltd. BiotechnologyHealth Technology Mitoconix Bio Ltd. develops novel therapeutics to improve mitochondrial health as a disease-modifying therapeutics for neurodegenerative diseases. The company was founded by Daria Mochly-Rosen in August 2016 and is headquartered in Ness Ziona, Israel. | Health Technology |
SpliSense Ltd.
SpliSense Ltd. Pharmaceuticals: MajorHealth Technology SpliSense Ltd. engages in the development of targeted therapies for genetic diseases based on splicing modulation treating the underlying root cause of the disease. The company was founded on November 10, 2016 and is headquartered in Jerusalem, Israel. | Health Technology |
